Los Angeles Capital Management
LAB icon

Los Angeles Capital Management’s Standard BioTools LAB Stock Holding History

Los Angeles Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75,580
Closed -$342K – 1611
2021
Q1 		$342K Buy
+75,580
New +$415K ﹤0.01% 1385
2019
Q3 		– Sell
-12,120
Closed -$149K – 1311
2019
Q2 		$149K Sell
12,120
-8,350
-41% -$106K ﹤0.01% 1305
2019
Q1 		$272K Buy
+20,470
New +$216K ﹤0.01% 1221
2018
Q4 		– Sell
-28,840
Closed -$216K – 1329
2018
Q3 		$216K Sell
28,840
-11,370
-28% -$80.8K ﹤0.01% 1317
2018
Q2 		$240K Buy
+40,210
New +$229K ﹤0.01% 1342

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Los Angeles Capital Management's LAB Position: Q2 2021 in Review

Los Angeles Capital Management sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 75,580 shares — an estimated $342K sold.

Los Angeles Capital Management first reported a position in LAB in Q2 2018 and held it in 5 quarters. The position peaked at $342K in Q1 2021. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

  • Los Angeles Capital Management reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 75,580 Standard BioTools shares in Q2 2021, an estimated $342K.
  • Los Angeles Capital Management first reported a position in Standard BioTools in Q2 2018 and held it in 5 quarters.
  • Los Angeles Capital Management's Standard BioTools position peaked at $342K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on Los Angeles Capital Management's 13F filing for Q2 2021, filed 5 Aug 2021.